Testing a focused ultrasound device to briefly open the blood-brain barrier in Alzheimer's disease
Tests the NMS-01 ultrasound device for safety in people with mild to moderate Alzheimer's.
Key facts
- Who runs it
- Neumous Inc.
- Where
- Seoul, South KoreaSee the site
- Trial code
- Registry title
- Pilot Clinical Trial to Assess the Safety of NMS-01 in Patients With Mild to Moderate Alzheimer's Disease
- Status
- Recruiting
- People taking part
- 10 people, planned
- Started
- 5 Jan 2026
- Expected to end
- 30 Nov 2026
- Type of study
- Interventional
- Treatments tested
- NMS-01
- Record updated
- 9 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 50 to 85 with mild to moderate Alzheimer's disease. They must have a caregiver and be able to tell the team about discomfort during the procedure.
- Age
- 50 to 85 years
- Sex
- All sexes
- Disease stage
- Probable Alzheimer's disease with a positive 18F-Florbetaben PET scan, a CDR global score of 1 to 2 and a K-MMSE score of 12 to 26.
- Earlier treatment
- A stable dose and regimen of approved Alzheimer's medicines for at least 3 months before screening.
- Biomarker or test result
- A previously confirmed positive 18F-Florbetaben (FBB) PET scan.
Main reasons for not taking part
- Severe delusions, hallucinations or agitation/aggression on the caregiver-rated inventory
- Uncontrolled psychiatric disorder, severe heart disease, uncontrolled hypertension or diabetes, or kidney function below 30 mL/min/1.73 m²
- Allergy to MRI or ultrasound contrast agents, or MRI-incompatible metal implants
- Bleeding disorders, or blood thinners within 2 weeks before or after the device treatment
- Pregnant or breastfeeding women, or being in another clinical trial within 90 days
The registry criteria, word for word
Show all 30 criteriaShow less
Who can take part
- Adults aged 50 to 85 years, inclusive
- Individuals previously diagnosed with probable Alzheimer's Disease (AD) by a specialist according to the National Institute on Aging and Alzheimer's Association (NIA-AA) 2011 criteria
- Individuals with a previously confirmed positive 18F-Florbetaben (FBB) position emission tmography (PET) scan
- Individuals with a Clinical Dementia Rating (CDR) global score between 1 and 2, inclusive
- Individuals with a total score on the Korean version of the Mini-Mental State Examination (K-MMSE) between 12 and 26, inclusive
- Individuals who have been on a stable dose and regimen of approved medications for the treatment of Alzheimer's disease for at least 3 months prior to screening
- Individuals capable of expressing sensations or discomfort to the investigator during the procedure
- Availability of a caregiver or informant who either lives with the participant or has sufficient contact (averaging at least 10 hours per week) to provide reliable information about the participant's overall functioning. This person must be able to accompany the participant to clinic visits, actively participate in clinical trial procedures, including interviews and questionnaire completion, and must voluntarily provide written informed consent for their own participation
- Participants (or their legally authorized representatives) must provide voluntary written informed consent for participation in the clinical trial. If a participant is illiterate and unable to provide written consent, verbal consent is permissible but must be formally documented. Furthermore, as all participants are considered vulnerable subjects, consent must also be provided and signed by a legal representative
Who cannot take part
- Subjects with standard contraindications for MR imaging, such as the presence of MRI-incompatible metallic implants
- Subjects with a history of receiving anticoagulant or antiplatelet agents within 2 weeks before or after the application of the investigational medical device, or who are scheduled to receive them
- Subjects currently participating in another clinical trial or who have participated in another clinical trial within 90 days prior to the screening date
- An uncontrolled psychiatric disorder/condition that could affect cognitive function or its assessment (e.g., schizophrenia, bipolar disorder, major depression). (However, subjects are permitted if they have been on a stable drug regimen without changes in dosage for at least the past 4 weeks)
- Subjects with pulmonary disease (e.g., pneumonia, pulmonary edema) confirmed by chest X-ray
- Subjects with a known sensitivity, allergy, or contraindication to MRI contrast agents (Gadovist® injection) or ultrasound contrast agents (SonoVue®)
- Subjects with a known sensitivity, allergy, or contraindication to local anesthetics or anesthetic agents used for conscious sedation during the procedure, if required
- More than 30% of the skull area in the intended ultrasound sonication path is covered by scar tissue, scalp disorders (e.g., eczema), or atrophied scalp
- A history of bleeding disorders
- Significant cardiac disease or unstable hemodynamic status (e.g., uncontrolled hypertension, arrhythmia, angina pectoris, etc.)
- Subjects who are HIV (Human Immunodeficiency Virus) positive and are at high risk of HIV encephalitis due to the influx of HIV into the brain parenchyma
- Subjects with a potential blood-borne infection that could enter the brain parenchyma and lead to meningitis or a brain abscess
- Subjects with uncontrolled hypertension or diabetes
- Any other condition for which the investigator deems participation in the clinical trial to be inappropriate for ethical reasons or because it could influence the trial results
- A severity score greater than 2 on any one of the following items on the Caregiver Administered Neuropsychiatry Inventory (CGA-NPI): "Delusions," "Hallucinations," or "Agitation/Aggression."
- Subjects meeting any of the following criteria based on MRI findings:
- Subjects with impaired renal function (Glomerular filtration rate <30 mL/min/1.73 m²)
- Severe brain atrophy that would preclude targeting
- Subjects with clinically significant abnormal findings on an electrocardiogram (ECG)
- Pregnant or lactating women
- Women of childbearing potential who do not agree to use a clinically appropriate method of contraception for the duration of the clinical trial
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 85 years old?
Where in South Korea
- Severance hospitalSeoul, South KoreaContact: NeumTaking people
About the trial
What the trial wants to find out
A single-center, single-arm, prospective, open-label, pilot clinical trial to evaluate the safety and efficacy of the Focused ultrasound stimulator system (NMS-01) for transient Blood-Brain Barrier (BBB) opening in patients with mild to moderate Alzheimer's disease
The group in the trial
- NMS-01Treatment being tested
BBB opening by ultrasound
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Single-center, Single-arm, Prospective, Open-label, Pilot Clinical Trial to Evaluate the Safety and Efficacy of the Focused Ultrasound Stimulator System (NMS-01) for Transient Blood-Brain Barrier (BBB) Opening in Patients With Mild to Moderate Alzheimer's Disease
- Plain-language title
- Testing a focused ultrasound device to briefly open the blood-brain barrier in Alzheimer's diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Fit questions
- Built from NCT07869238, who can take part
- Record updated
- 9 October 2026